News and Announcements
CollinStar Capital Invests in Shivom!
- Published April 03, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
-
CollinStar Capital invests into the Shivom project
-
Shivom welcomes CollinStar’s expertise and contribution to their work building the largest genomic and healthcare data hub around the globe
CollinStar Capital, the leaders in fintech and digital currency, pools a large investment into the Shivom project.
CollinStar is one of the biggest Australian-based asset management firms, and are experts in blockchain technology and infrastructure, as well as a proficient cryptocurrency investor. Shivom is very excited to welcome CollinStar’s expertise and contribution to our work building the largest genomic and healthcare data hub around the globe. We are confident that CollinStar’s contribution will help propel our vision forward, and with their backing, we are on our way to changing the healthcare landscape.
Shivom is thrilled to have gained the confidence of blockchain and cryptocurrency experts and we look forward to many more of these announcements in the coming days.
These milestones help motivate us to make Shivom the largest project of its kind, and with backers such as CollinStar, we are confident we can make this happen!
We are extremely grateful for all the support and encouragement we have received from our community thus far and are committed to keep the momentum going.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
